MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jchf.2020.11.009

Медицинская библиотека · JACC. Heart failure · 2021

Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.

Shen Li, Kristensen Søren Lund, Bengtsson Olof, Böhm Michael, de Boer Rudolf A, Docherty Kieran F, Inzucchi Silvio E, Katova Tzvetana, Køber Lars, Kosiborod Mikhail N, Langkilde Anna Maria, Lindholm Daniel, Martinez M Felipe A, O'Meara Eileen, Nicolau Jose C, Petrie Mark C, Ponikowski Piotr, Sabatine Marc S, Schou Morten, Sjöstrand Mikaela, Solomon Scott D, Jhund Pardeep S, McMurray John J V

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

The purpose of this study was to assess the efficacy and safety of dapagliflozin in patients taking or not taking an mineralocorticoid receptor antagonist (MRA) at baseline in the DAPA-HF (Dapagliflozin And Prevention of Adverse outcomes in Heart Failure) trial.

BACKGROUND

MRAs and sodium glucose co-transporter 2 inhibitors each have diuretic activity, lower blood pressure, and reduce glomerular filtration rate (GFR). Therefore, it is important to investigate the safety, as well as efficacy, of their combination.

METHODS

A total of 4,744 patients with heart failure with reduced ejection fraction (HFrEF) were randomized to placebo or dapagliflozin 10 mg daily. The efficacy of dapagliflozin on the primary composite outcome (cardiovascular death or episode of worsening heart failure) and its components was examined according to MRA use, as were predefined safety outcomes.

RESULTS

A total of 3,370 patients (71%) were treated with an MRA and they were younger (65 vs. 69 years of age), less often from North America (9% vs. 26%), had worse New York Heart Association functional class (35% vs. 25% in class III/IV), lower left ventricular ejection fraction (30.7% vs. 31.9%) and systolic blood pressure (120.3 vs. 125.5 mm Hg), but higher estimated GFR (67.1 vs. 62.6 ml/min/1.73 m2), than patients not taking an MRA. The benefit of dapagliflozin compared with placebo was similar in patients taking or not taking an MRA: hazard ratio: 0.74 (95% confidence interval [CI]: 0.63 to 0.87) versus 0.74 (95% CI: 0.57 to 0.95), respectively, for the primary endpoint (p value for interaction = 0.97); similar findings were observed for secondary endpoints. In both MRA subgroups, safety outcomes were similar in patients randomized to dapagliflozin or placebo.

CONCLUSIONS

Dapagliflozin was similarly efficacious and safe in patients with HFrEF taking or not taking an MRA, supporting the use of both drugs together. (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [DAPA-HF]; NCT03036124).

Для цитирования: Shen Li, Kristensen Søren Lund, Bengtsson Olof, Böhm Michael, de Boer Rudolf A, Docherty Kieran F, Inzucchi Silvio E, Katova Tzvetana, Køber Lars, Kosiborod Mikhail N, Langkilde Anna Maria, Lindholm Daniel, Martinez M Felipe A, O'Meara Eileen, Nicolau Jose C, Petrie Mark C, Ponikowski Piotr, Sabatine Marc S, Schou Morten, Sjöstrand Mikaela, Solomon Scott D, Jhund Pardeep S, McMurray John J V. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.. JACC. Heart failure. 2021. DOI: 10.1016/j.jchf.2020.11.009.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.